Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Serodus Begins IIa Trial Against ISH | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Serodus Begins IIa Trial Against ISH

Lead compound to test against hypertension in the elderly

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Serodus ASA has begun its first Phase IIa study with SER100 in patients suffering from Isolated Systolic Hypertension (ISH). The first patient has been enrolled in the study; the company plans to enroll a total of 30 patients during the next few months. The company expects that the last patient will be dosed in the end of the 1Q14.

Isolated Systolic Hypertension (ISH) is the leading hypertensive disease in elderly people. SER100 is a new compound with a first-in-class mode of action; the company plans to demonstrate through through the IIa trial that the drug is safe and can provide a selective reduction of systolic blood pressure in elderly, treatment-resistant ISH patients.

The participating hospitals are Oslo University Hospital (NO), Medi3 Innlandet (NO), Turku University Hospital (FI), Valkeakoski District Hospital (FI), Brighton and Sussex University Hospital (UK) and Semmelweis University Hospital (HUN).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics